Samsung Bioepis Co., Ltd.
Quick facts
| Founded | 2012 |
|---|
Marketed products
- Lucentis (ranibizumab) · Ophthalmology
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. - SB5 · Immunology; Rheumatology
SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - SB5 (Adalimumab Biosimilar) · Immunology
SB5 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Phase 3 pipeline
- Herceptin (trastuzuamb) · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. - Prolia® (Denosumab) · Osteoporosis, Bone-related disorders
Prolia works by binding to RANKL, a protein involved in the formation and activation of osteoclasts, which are cells that break down bone. - SB27 · Rheumatology
SB27 is a biosimilar to adalimumab, a TNF-alpha inhibitor. - SB8 · Oncology
SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. - Soliris (eculizumab) · Immunology
Soliris works by inhibiting the complement system by blocking the action of C5.
Phase 2 pipeline
- Adalimumab PFS and Pen · Immunology
TNF-alpha inhibitor
Phase 1 pipeline
- EU Remicade
- EU sourced Enbrel
- EU sourced Herceptin®
- EU sourced Humira®
- Pen of SB5
- PFS of SB5
- SB26
- US Remicade
- US sourced Enbrel
- US sourced Herceptin®
- US sourced Humira®
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: